A Phase 1 interventional study of JNJ-30979754 15 mg/m2 and JNJ-30979754 20 mg/m2 in Myelodysplastic Syndrome, sponsored by Janssen Pharmaceutical K.K.. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-12-09.
Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 40th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2008, is one of 18 in phase 1, and was the 22nd registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
West Virginia University · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 60+
Clinical Hub for Interventional Research (CHOIR) · Sites in Australia
Ages 18+
By country, each count listing its studies:
Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 49 · Phase 3 6 · Phase 4 3
First in 1995; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is close to the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 43 across the 74 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Pharmaceutical K.K., one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutical K.K. is the lead sponsor of 126 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 7 (50%) have results posted.
21 studies in Myelodysplastic Syndromes by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 16 finished, 6 (38%) have results posted.
Among the 21 studies in Myelodysplastic Syndromes by Johnson & Johnson, this one is the 10th largest by enrollment of the 17 interventional ones that give a count, is one of 6 that started in 2008, is one of 6 in phase 1, and was the 8th registered.
Johnson & Johnson’s Myelodysplastic Syndromes studies by the year they started, since 1999.
2 of the studies testing decitabine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923488West Virginia UniversityLeflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes | 2027-10 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, from their registry updates:
Among Johnson & Johnson’s 21 in Myelodysplastic Syndromes:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to to determine the recommended dose level of JNJ-30979754 (decitabine) as well as to assess the safety and effectiveness in patients with Myelodysplastic Syndrome (MDS).
This is an open-label (both physician and patient know the name and dosage of drug), multi-center study. This study consists of two parts, Phase I and Phase II. In Phase I, approximately 9 participants will be enrolled ie, 3 participants for dose level 1 (15 mg/m2 of JNJ-30979754) and 6 participants for dose level 2 (20 mg/m2 of JNJ-30979754). Once the tolerability of 20 mg/m2 is confirmed additional 30 participants will be included to receive 20 mg/m2 and approximate total participants in Phase II will be 36. This study will include screening period (within 14 days prior to the day of initial administration of Cycle 1) and dosing period (1 cycle consists of administration of study medication for first 5 consecutive days + rested for 23 days; ie, total 28 days). Cycles will be reapeated in participants in whom decitabine was expected to be effective. Safety evaluations will include assessment of adverse events, vital signs, body weight, clinical laboratory tests: hematology, blood biochemistry and urinalysis, cardiopulmonary function tests: ECG, chest X ray and oximeter analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
Drug: JNJ-30979754 15 mg/m2
JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1
Drug: JNJ-30979754 20 mg/m2
JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles
Drug: JNJ-30979754 20 mg/m2
Drug page: Decitabine
JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
Also known as: decitabine
Drug page: Decitabine
Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
Also known as: decitabine
Phase II: Overall Remission Rate (ORR): Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR) - as Per International Working Group (IWG) Response Criteria (2000)
IWG response criteria (2000) - CR: bone marrow evaluations show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia and PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes.
Time frame: Up to 1 years after the last participant enrolled
Phase I and II: Number of Participants Who Experienced Adverse Events
Time frame: Up to 1.5 years after the last participant enrolled
Phase I: Maximum Observed Plasma Concentration of Decitabine (Cmax)
Time frame: Before dosing (Pre-dose), 30 min, 60 min (end of infusion), 65 min, 75 min, 90 min, 120 min, 180 min, 240 min after the start of decitabine infusion on Day 1 and Day 5 of 28-Days Cycle 1
Phase I: Area Under the Plasma Concentration-time Curve (AUC)
Area under the curve from time zero to extrapolated infinite time (AUC Infinity) and area under the curve from time zero to last quantifiable concentration (AUC Last).
Time frame: Before dosing (Pre-dose), 30 min, 60 min (end of infusion), 65 min, 75 min, 90 min, 120 min, 180 min, 240 min after the start of decitabine infusion on Day 1 and Day 5 of 28-Days Cycle 1
Phase I: Number of Participants Who Achieved Complete Remission (CR)+Partial Remission (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)
IWG response criteria (2000) - CR: bone marrow evaluations (mCR) show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia; PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes; HI: hemoglobin \< 11 g/dL (erythroid); platelet \< 100,000/mL; neutrophils \< 1,000/mL.
Time frame: Up to 28 Days of treatment Cycle 1
Phase II: Median Time to Remission
Median time required for the participants to achieve remission (complete remission+partial remission).
Time frame: Up to 1.5 years after the last participant enrolled
Phase II: Median Time to Improvement
Median time required for the participants to achieve overall improvement (complete remission+partial remission+hematologic improvement)
Time frame: Up to 1.5 years after the last participant enrolled
Phase II: Median Duration of Remission
Median time duration for which participants achieved remission (complete remission+partial remission).
Time frame: Up to 1.5 years after the last participant enrolled
Phase II: Median Duration of Overall Improvement
Median time duration for which participants achieved overall improvement (complete remission+partial remission+hematologic improvement).
Time frame: Up to 1.5 years after the last participant enrolled
Phase II: Overall Improvement Rate: Number of Participants Who Achieved Complete Response (CR)+Partial Response (PR)+Hematological Improvement (HI) - as Per International Working Group (IWG) Response Criteria (2000)
IWG response criteria (2000) - CR: bone marrow evaluations (mCR) show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia and PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes. HI: hemoglobin \< 11 g/dL (erythroid); platelet \< 100,000/mL; neutrophils \< 1,000/mL.
Time frame: Up to 1.5 years after the last participant enrolled
Phase II: Number of Participants With Cytogenic Response - as Per International Working Group (IWG) Response Criteria 2000 (Major/Minor) and IWG 2006 (Complete/Partial)
IWG 2000 - Major: disappearance of cytogenetic abnormality; Minor: 50% or more reduction in abnormal metaphases. IWG 2006 - Complete: disappearance of the chromosomal abnormality without appearance of new ones; Partial: At least 50% reduction of the chromosomal abnormality.
Time frame: Up to 1.5 years after the last participant enrolled
39 participants were enrolled at multiple sites in Japan.
| Milestone | Phase I: 15 mg/m2 | Phase I and II: 20 mg/m2 |
|---|---|---|
| Started | 3 | 36 |
| Treated | 3 | 34 |
| Completed | 0 | 7 |
| Not completed | 3 | 29 |
| Withdrew: Disease progression | 2 | 13 |
| Withdrew: Adverse event | 1 | 7 |
| Withdrew: Specified organ function not met | 0 | 1 |
| Withdrew: Physician decision | 0 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Other | 0 | 1 |
| Withdrew: Participants not treated | 0 | 2 |
IWG response criteria (2000) - CR: bone marrow evaluations show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia and PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes.
| Participants | Phase II: 20 mg/m2 |
|---|---|
| CR | 7 |
| PR | 2 |
| Participants | Phase I: 15 mg/m2 | Phase I: 20 mg/m2 | Phase II: 20 mg/m2 |
|---|---|---|---|
| Phase I and II: Number of Participants Who Experienced Adverse Events | 3 | 6 | 34 |
| ng/mL | Phase I: 15 mg/m2 | Phase I: 20 mg/m2 |
|---|---|---|
| Day 1 | 151.7 ± 28.729 | 166.4 ± 17.170 |
| Day 5 | 142.0 ± 40.635 | 190.6 ± 54.679 |
Area under the curve from time zero to extrapolated infinite time (AUC Infinity) and area under the curve from time zero to last quantifiable concentration (AUC Last).
| ng*h/mL | Phase I: 15 mg/m2 | Phase I: 20 mg/m2 |
|---|---|---|
| AUC Last - Day 1 | 149.0 ± 41.102 | 155.2 ± 15.754 |
| AUC Last - Day 5 | 136.0 ± 37.855 | 152.0 ± 15.712 |
| AUC Infinity - Day 1 | 150.0 ± 40.777 | 156.1 ± 15.497 |
| AUC Infinity - Day 5 | 136.9 ± 37.897 | 151.2 ± 17.617 |
IWG response criteria (2000) - CR: bone marrow evaluations (mCR) show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia; PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes; HI: hemoglobin \< 11 g/dL (erythroid); platelet \< 100,000/mL; neutrophils \< 1,000/mL.
| Participants | Phase I: 15 mg/m2 | Phase I: 20 mg/m2 |
|---|---|---|
| PR | 1 | 1 |
| HI | 1 | 2 |
Median time required for the participants to achieve remission (complete remission+partial remission).
| Days | Phase II: 20 mg/m2 |
|---|---|
| Phase II: Median Time to Remission | 130.0 (67.0 to 208.0) |
Median time required for the participants to achieve overall improvement (complete remission+partial remission+hematologic improvement)
| Days | Phase II: 20 mg/m2 |
|---|---|
| Phase II: Median Time to Improvement | 26.5 (22.0 to 36.0) |
Median time duration for which participants achieved remission (complete remission+partial remission).
| Days | Phase II: 20 mg/m2 |
|---|---|
| Phase II: Median Duration of Remission | 489 (294 to 489) |
Median time duration for which participants achieved overall improvement (complete remission+partial remission+hematologic improvement).
| Days | Phase II: 20 mg/m2 |
|---|---|
| Phase II: Median Duration of Overall Improvement | 532 (147 to 554) |
IWG response criteria (2000) - CR: bone marrow evaluations (mCR) show \< 5% blasts; no dysplasia; normal maturation of all cell lines and peripheral blood shows hemoglobin ≥ 11 g/dL; neutrophils ≥ 1,500/mL; platelets ≥ 100,000/mL; 0% blasts; no dysplasia and PR: same as CR, except blasts decrease by ≥ 50% or lower French-American-British (FAB) classification of Myelodysplastic Syndromes. HI: hemoglobin \< 11 g/dL (erythroid); platelet \< 100,000/mL; neutrophils \< 1,000/mL.
| Participants | Phase II: 20 mg/m2 |
|---|---|
| CR | 7 |
| PR | 2 |
| HI | 5 |
IWG 2000 - Major: disappearance of cytogenetic abnormality; Minor: 50% or more reduction in abnormal metaphases. IWG 2006 - Complete: disappearance of the chromosomal abnormality without appearance of new ones; Partial: At least 50% reduction of the chromosomal abnormality.
| Participants | Phase II: 20 mg/m2 |
|---|---|
| Major/Complete | 6 |
| Minor/Partial | 1 |
| No response | 10 |
| Not estimable | 3 |
Collected over Up to 1.5 years after the last participant enrolled. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I - 15 mg/m2 Group | — | 1/3 (33.3%) | 3/3 (100%) |
| Phase I - 20 mg/m2 Group | — | 1/6 (16.7%) | 6/6 (100%) |
| Phase II: 20 mg/m2 | — | 11/34 (32.4%) | 34/34 (100%) |
| Event | Phase I - 15 mg/m2 Group | Phase I - 20 mg/m2 Group | Phase II: 20 mg/m2 |
|---|---|---|---|
| PneumoniaInfections and infestations | 1/3 | 0/6 | 4/34 |
| CellulitisInfections and infestations | 0/3 | 1/6 | 1/34 |
| PharyngitisInfections and infestations | 0/3 | 1/6 | 1/34 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 1/6 | 2/34 |
| Wound complicationInjury, poisoning and procedural complications | 0/3 | 1/6 | 1/34 |
| SepsisInfections and infestations | 0/3 | 0/6 | 2/34 |
| Neutropenic infectionInfections and infestations | 0/3 | 0/6 | 1/34 |
| Pneumonia fungalInfections and infestations | 0/3 | 0/6 | 1/34 |
| Enterocolitis viralInfections and infestations | 0/3 | 0/6 | 1/34 |
| AneamiaBlood and lymphatic system disorders | 0/3 | 0/6 | 1/34 |
| Event | Phase I - 15 mg/m2 Group | Phase I - 20 mg/m2 Group | Phase II: 20 mg/m2 |
|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 3/3 | 6/6 | 34/34 |
| AnaemiaBlood and lymphatic system disorders | 3/3 | 6/6 | 29/34 |
| LymphopeniaBlood and lymphatic system disorders | 3/3 | 5/6 | 29/34 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/3 | 6/6 | 27/34 |
| NeutropeniaBlood and lymphatic system disorders | 3/3 | 5/6 | 26/34 |
| C-reactive protein increasedInvestigations | 3/3 | 1/6 | 1/34 |
| Blood urine presentInvestigations | 0/3 | 5/6 | 11/34 |
| Neutropenic infectionInfections and infestations | 2/3 | 3/6 | 15/34 |
| StomatitisGastrointestinal disorders | 2/3 | 3/6 | 9/34 |
| Transfusion reactionInjury, poisoning and procedural complications | 2/3 | 1/6 | 11/34 |
For Baseline characteristics analysis, number of participants treated were analyzed (37) instead of number of participants enrolled (39). 2 enrolled participants were not treated.
| Age Continuous(Years) | Phase I: 15 mg/m2 | Phase I and II: 20 mg/m2 | Total |
|---|---|---|---|
| Mean | 68.7 ± 2.08 | 68.5 ± 7.09 | 68.5 ± 6.81 |
| Age, Customized(Participants) | Phase I: 15 mg/m2 | Phase I and II: 20 mg/m2 | Total |
|---|---|---|---|
| <65 years | 0 | 10 | 10 |
| >= 65 and <= 74 years | 3 | 17 | 20 |
| >=75 years | 0 | 7 | 7 |
| Sex: Female, Male(Participants) | Phase I: 15 mg/m2 | Phase I and II: 20 mg/m2 | Total |
|---|---|---|---|
| Female | 0 | 8 | 8 |
| Male | 3 | 26 | 29 |
The record gives a start of Jul 2008, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Decitabine